Jan Peter de Geus

Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.

M. J. van den Bent, M. Weller, T. Gorlia, 2021, European journal of cancer.